Apoptosis has been implicated in the pathogenesis of marrow failure in MDS and the coexistence of marrow hypercellularity along with blood cytopenias was seen as evidence of extreme cell death of mainly mature cells in the marrow (ineffective hematopoiesis). We investigated apoptosis in 53 patients with MDS, by using single-step DNA extraction and gel electrophoresis and then by separating fresh marrow mononuclear cells in CD34+ and CD34 − populations and in situ single cell evaluation of the process. We also studied the expression of apoptosis-related genes, in total and separated mononuclear marrow cells and correlated the findings with clinical and laboratory characteristics. Patients with apoptosis had increased marrow cellularity, longer overall survival and a longer period for transformation to AML. In 'good' prognosis MDS patients, total mononuclear marrow cells, as well as isolated populations of CD34+ and CD34 − cells showed significant degrees of apoptosis; in 'poor' prognosis cases, however, apoptosis was evident only in a large percentage of CD34 + marrow cells and not in total or CD34 − cells. Absence of expression of both c-myc and p53 in total marrow cells was associated with significant degrees of apoptosis and in isolated CD34+ and CD34 − marrow cells the phenomenon was inversely correlated with the level of bcl-2 expression. In conclusion, marrow apoptosis is detected in both CD34+ and CD34 − cells in early MDS and seems to be restricted to CD34+ cells in advanced MDS cases.
Summary. Forty Caucasian patients with primary acquired sideroblastic anaemia (SA), were investigated for the presence of the Cys282Tyr and/or His63Asp mutation as possible cofactor(s) for iron overload. One patient was heterozygous for the Cys282Tyr mutation and 13 heterozygotes and one homozygote for the His63Asp mutation were found (no difference compared with controls). SA patients with normal codon 63 had a mean ferritin level of 923 Ϯ 815 mg/l whereas those with codon 63 mutation had 769 Ϯ 577 mg/l (P ¼ 0·64). We conclude that ineffective erythropoiesis with no associated mutation in the HFE gene can lead to iron overload in SA patients.
Introduction - Aims: Patients with refractory anemia with ringed sideroblasts (RARS) treated with erythropoietin (rh-Epo), usually exhibit less favorable response, comparing to other types of MDS. The addition of G-CSF improves response rate and newly diagnosed patients, transfusion independent, with higher hemoglobin (Hb) and low plasma Epo levels (<200 mIU/ml) are the best candidates to respond to combination regimens. We investigated whether the in vitro response of committed progenitor cells to growth factors and the detection of apoptosis in BM cells could predict the clinical response to treatment in these patients. Patients and methods: Sixteen anemic patients with RARS (4 female, 12 male, median age 71 years) were included in the study. The median Hb was 8.8 g/dl and 12 patients were transfusion-dependent. Karyotype was available in 13 cases and it was normal in 10 and abnormal in 3. IPSS was low in 8 cases and intermediate-1 in 5. Bone marrow colony-forming cells (CFC) were cultured in classical semisolid medium (with Epo alone) and the growth pattern was compared to that in a medium enriched with SCF, G-CSF, GM-CSF, IL-3 and IL-6. The ratio of developed colonies/105 marrow mononuclear cells with the enriched vs. the standard medium was determined as Increment Index (I.I.). Presence of apoptosis was investigated in BM aliquots of 11 patients with a DNA fragmentation assay. Patients were treated with rh-Epo 100-300 IU/Kg plus G-CSG 0.1-0.2 μg/kg sc. in alternative days and response was evaluated after 6 months of treatment. The in vitro response of progenitor cells to growth factors was correlated with the in vivo response to treatment. Every kind of response was also correlated with the presence of apoptosis, as well as with the clinical and laboratory features of the patients. Results: The enriched medium led always to an increased total CFC (mean I.I. 3.55, range 1.5–12.3) and BFU-E number (mean I.I. 2.4, range 1.2–6.1). Apoptosis was detected in 7/11 marrow samples, and its presence was associated with decreased number of BFU-E and of total CFC colonies, with the standard (BFU-E: 6.7±4.2 vs. 15±19, p=0.042, total CFC: 17±9 vs. 34±60, p=0.012) and the enriched medium (BFU-E: 15±11 vs. 31±60, p=0.048, total CFC: 63±37 vs. 84±113, p=0.026). However, apoptosis had no impact in the I.I of both type of colonies. Six patients (37.5%) responded to treatment, and 2 of them became transfusion-independent. All but one responded patients had low IPSS, higher absolute neutrophil count (2.75±0.7 vs. 1.7±0.9 x 109/l, p=0.037), and significantly lower serum Epo levels (62±43 vs. 209±93 IU/ml, p=0.004). Two of 5 responders and 5/6 non-responders exhibited apoptotic model in their marrow (p: n.s.). There was no difference in the I.I. between responders and non-responders to treatment (BFU-E: 2.75±1.17 vs. 2.42±1.51, p: ns, CFC: 2.8±1.16 vs. 3.16±4.1, p: ns). One of the 6 responders and 3/10 non-responders evolved to a more aggressive MDS or AML. Total median survival was also not different between the two groups of patients (responders: 93 months, non-responders: 67 months, p=0.281). Conclusive remarks: Neither the in vitro response of BM progenitors to growth factors, nor the presence of apoptosis in BM cells, could predict the clinical response to treatment with the used combination of rh-Epo+G-CSF in this group of patients with RARS.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.